

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS	iii
ABSTRACT (in English)	iv
ABSTRACT (in Thai)	vi
TABLE OF CONTENTS	viii
LIST OF TABLES	xvi
LIST OF FIGURES	xix
LIST OF SCHEMES	xxiv
ABBREVIATIONS AND SYMBOLS	xxvii
 CHAPTER 1 INTRODUCTION	
1.1 Statement and significance of the problem: Malaria and world health	1
1.2 The classification of antimalarial agent	5
1.2.1 4-Aminoquinolines and arylamino alcohols	5
1.2.1.1 4-Aminoquinolines	5
1.2.1.2 Arylamino alcohols	7
1.2.2 8-Aminoquinolines	8
1.2.3 Artemisinin and synthetic peroxides	9
1.2.4 Chimeric molecules	11
1.2.5 Antifolates	12
1.2.6 Compounds acting on the respiratory chain	13
1.2.7 Antibiotics	14
1.2.8 Diamidines	14
1.2.9 Inhibitors of phospholipid metabolism	15
1.2.10 Inhibitors of isoprenoid biosynthesis	15
1.3 Literature reviews	17
1.3.1 Dimethyl itaconate–anthracene adduct ((±)-74)	17
1.3.2 Piperine and their derivatives	18

TABLE OF CONTENTS (CONTINUED)

	Page
1.3.3 Cinnamic acid derivatives	19
1.4 Objectives	20
CHAPTER 2 EXPERIMENTAL	
2.1 Preparation of piperine (75) and piperic acid (105)	23
2.1.1 Extraction of 5-(3,4-methylenedioxy)phenyl-1-(1''-piperidinyl)-2 <i>E</i> ,4 <i>E</i> -pentadien-1-one (piperine, 75)	23
2.1.2 Preparation of 5-(3,4-methylenedioxy)phenyl-2 <i>E</i> ,4 <i>E</i> -pentadienoic acid (piperic acid, 105)	24
2.2 Preparation of pentadien amide derivatives 112b-d from piperic acid (105)	26
2.2.1 Preparation of 5-(3,4-methylenedioxy)phenyl-1-(1-pyrrolidinyl)-2 <i>E</i> ,4 <i>E</i> -pentadien-1-one (112b)	26
2.2.2 Preparation of 5-(3,4-methylenedioxy)phenyl-1-(1- <i>N,N</i> -dibutyl)-2 <i>E</i> ,4 <i>E</i> -pentadien-1-one (112c)	28
2.2.3 Preparation of 5-(3,4-methylenedioxy)phenyl-1-(1- <i>N,N</i> -diisopropyl)-2 <i>E</i> ,4 <i>E</i> -pentadien-1-one (112d)	30
2.3 Preparation of α,β -unsaturated amide derivatives 113a-d from 3,4-methylenedioxy cinnamic acid (106)	33
2.3.1 Preparation of 3-(3,4-methylenedioxy)phenyl-1-(1-piperidinyl)-2 <i>E</i> -propen-1-one (113a)	33
2.3.2 Preparation of 3-(3,4-methylenedioxy)phenyl-1-(1-pyrrolidinyl)-2 <i>E</i> -propen-1-one (113b)	35
2.3.3 Preparation of 3-(3,4-methylenedioxy)phenyl-1-(1- <i>N,N</i> -dibutyl)-2 <i>E</i> -propen-1-one (113c)	37
2.3.4 Preparation of 3-(3,4-methylenedioxy)phenyl-1-(1- <i>N,N</i> -diisopropyl)-2 <i>E</i> -propen-1-one (113d)	39
2.4 Preparation of α,β -unsaturated amide derivatives 114a-d from cinnamic acid (107)	41

TABLE OF CONTENTS (CONTINUED)

	Page
2.4.1 Preparation of 3-phenyl-1-(1-piperidiny)-2 <i>E</i> -propen-1-one (114a)	41
2.4.2 Preparation of 3-phenyl-1-(1-pyrrolidiny)-2 <i>E</i> -propen-1-one (114b)	43
2.4.3 Preparation of 3-phenyl-1-(1- <i>N,N</i> -dibutyl)-2 <i>E</i> -propen-1-one (114c)	45
2.4.4 Preparation of 3-phenyl-1-(1- <i>N,N</i> -diisopropyl)-2 <i>E</i> -propen-1-one (114d)	47
2.5 Preparation of 11-methoxyacetyl-11-methoxycarbonyl-9,10-dihydro-9,10-ethanoanthracene ((±)- 74)	49
2.6 Syntheses of racemic spirocyclopentanone–anthracene adduct derivatives (±)- 115b-i , - <i>ii</i> – (±)- 115d-i , - <i>ii</i>	51
2.6.1 Syntheses of 3'-methoxycarbonyl-4'-(2-(3,4-methylenedioxy)phenyl)vinyl-5'-pyrrolidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 115b-i and (±)- 115b-ii)	51
2.6.2 Syntheses of 5'-(<i>N,N</i> -dibutylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(2-(3,4-methylenedioxy)phenyl)vinyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 115c-i and (±)- 115c-ii)	57
2.6.3 Syntheses of 5'-(<i>N,N</i> -diisopropylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(2-(3,4-methylenedioxy)phenyl)vinyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 115d-i and (±)- 115d-ii)	62
2.7 Syntheses of racemic spirocyclopentanone–anthracene adduct derivatives (±)- 116a-i , - <i>ii</i> – (±)- 116d-i , - <i>ii</i>	67

TABLE OF CONTENTS (CONTINUED)

	Page
2.7.1 Syntheses of 3'-methoxycarbonyl-4'-(3,4-methylenedioxy)phenyl-5'-piperidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 116a-i and (±)- 116a-ii)	67
2.7.2 Syntheses of 3'-methoxycarbonyl-4'-(3,4-methylenedioxy)phenyl-5'-pyrrolidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 116b-i and (±)- 116b-ii)	72
2.7.3 Syntheses of 5'-(<i>N,N</i> -dibutylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(3,4-methylenedioxy)phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 116c-i and (±)- 116c-ii)	77
2.7.4 Syntheses of 5'-(<i>N,N</i> -diisopropylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(3,4-methylenedioxy)phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 116d-i and (±)- 116d-ii)	82
2.8 Syntheses of racemic spirocyclopentanone-anthracene adduct derivatives ((±)- 117a-i , - <i>ii</i> – ((±)- 117d-i , - <i>ii</i>)	87
2.8.1 Syntheses of 3'-methoxycarbonyl-4'-phenyl-5'-piperidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 117a-i and (±)- 117a-ii)	87
2.8.2 Syntheses of 3'-methoxycarbonyl-4'-phenyl-5'-pyrrolidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 117b-i and (±)- 117b-ii)	92
2.8.3 Syntheses of 5'-(<i>N,N</i> -dibutylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracene ((±)- 1107-i and (±)- 117c-ii)	96

TABLE OF CONTENTS (CONTINUED)

	Page
2.8.4 Syntheses of 5'-(<i>N,N</i> -diisopropylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 117d-i and (±)- 117d-ii)	101
 CHAPTER 3 RESULTS AND DISCUSSION	
3.1 Syntheses of racemic spirocyclopentanone–anthracene adducts ((±)- 76-i and (±)- 76-ii) and cyclopentanones ((±)- 134-i and (±)- 134-ii) from piperine (75)	106
3.1.1 Syntheses of 3'-methoxycarbonyl-4'-(2-(3,4-methylenedioxy)phenyl)vinyl-5'-piperidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 76-i and (±)- 76-ii) from piperine (75)	106
3.1.2 Syntheses of 2,2-dimethyl-3-methoxycarbonyl-4-(2-(3,4-methylenedioxy)phenyl)vinyl-5- piperidinecarbonyl-1-cyclopentanones ((±)- 134-i and (±)- 134-ii) from piperine (75)	115
3.2 Syntheses of racemic spirocyclopentanone–anthracene adduct derivatives (±)- 115b-i , - <i>ii</i> – (±)- 115d-i , - <i>ii</i> from pentadien amide derivatives 112b-d	120
3.2.1 Syntheses of 3'-methoxycarbonyl-4'-(2-(3,4-methylenedioxy)phenyl)vinyl-5'-pyrrolidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 115b-i and (±)- 115b-ii) from pentadien amide 112b	120
3.2.2 Syntheses of 5'-(<i>N,N</i> -dibutylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(2-(3,4-methylenedioxy)phenyl)vinyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes ((±)- 115c-i and (±)- 115c-ii) from pentadien amide 112c	126

TABLE OF CONTENTS (CONTINUED)

	Page
3.2.3 Syntheses of 5'-(<i>N,N</i> -diisopropylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(2-(3,4-methylenedioxy)phenyl)-vinyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 115d-i and ($\pm$)- 115d-ii) from pentadien amide 112d	132
3.3 Syntheses of racemic spirocyclopentanone–anthracene adduct derivatives ($\pm$)- 116a-i , - <i>ii</i> – ($\pm$)- 116d-i , - <i>ii</i> from α,β -unsaturated amide derivatives 113a-d	139
3.3.1 Syntheses of 3'-methoxycarbonyl-4'-(3,4-methylenedioxy)-phenyl-5'-piperidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 116a-i and ($\pm$)- 116a-ii) from α,β -unsaturated amide 113a	139
3.3.2 Syntheses of 3'-methoxycarbonyl-4'-(3,4-methylenedioxy)-phenyl-5'-pyrrolidinecarbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 116b-i and ($\pm$)- 116b-ii) from α,β -unsaturated amide 113b	145
3.3.3 Syntheses of 5'-(<i>N,N</i> -dibutylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(3,4-methylenedioxy)phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-thanoanthracenes (($\pm$)- 116c-i and ($\pm$)- 116c-ii) from α,β -unsaturated amide 113c	151
3.3.4 Syntheses of 5'-(<i>N,N</i> -diisopropylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-(3,4-methylenedioxy)phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 116d-i and ($\pm$)- 116d-ii) from α,β -unsaturated amide 113d	157
3.4 Syntheses of racemic spirocyclopentanone–anthracene adduct derivatives ($\pm$)- 117a-i , - <i>ii</i> – ($\pm$)- 117d-i , - <i>ii</i> from α,β -unsaturated amide derivatives 114a-d	163


TABLE OF CONTENTS (CONTINUED)

	Page
3.4.1 Syntheses of 3'-methoxycarbonyl-4'-phenyl-5'-piperidine-carbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 117a-i and ($\pm$)- 117a-ii) from α,β -unsaturated amide 114a	163
3.4.2 Syntheses of 3'-methoxycarbonyl-4'-phenyl-5'-pyrrolidine-carbonyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 117b-i and ($\pm$)- 117b-ii) from α,β -unsaturated amide 114b	168
3.4.3 Syntheses of 5'-(<i>N,N</i> -dibutylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 117c-i and ($\pm$)- 117c-ii) from α,β -unsaturated amide 114c	173
3.4.4 Syntheses of 5'-(<i>N,N</i> -diisopropylcarboxamid-1-yl)-3'-methoxycarbonyl-4'-phenyl-1'-cyclopentanone-2'-spiro-11-9,10-dihydro-9,10-ethanoanthracenes (($\pm$)- 117d-i and ($\pm$)- 117d-ii) from α,β -unsaturated amide 114d	179
3.5 Syntheses of spirocyclopentanone–anthracene adduct dimers (($\pm$)- 147a-c)	184
3.5.1 Preparation of methyl itaconate–anthracene adduct dimers (($\pm$)- 146a-c) from methyl itaconate–anthracene adduct mono acid (($\pm$)- 143)	184
3.5.2 Syntheses of spirocyclopentanone–anthracene adduct dimers (($\pm$)- 147a-c)	184
3.6 Bioactivity and Cytotoxicity Tests	185
3.7 Activity to Cytochrome 450 (CYP 450)	190

CHAPTER 4 CONCLUSIONS

TABLE OF CONTENTS (CONTINUED)

	Page
REFERENCES	198
APPENDIX	210
CURRICULUM VITAE	248



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University

All rights reserved

LIST OF TABLES

Table		Page
1.1	Antimalarial drugs	4
2.1	Data of piperine (75)	23
2.2	Data of piperic acid (105)	24
2.3	Data of pentadiene amide 112b	27
2.4	Data of pentadiene amide 112c	28
2.5	Data of pentadiene amide 112d	30
2.6	Data of α,β -unsaturated amide 113a	33
2.7	Data of α,β -unsaturated amide 113b	35
2.8	Data of α,β -unsaturated amide 113c	37
2.9	Data of α,β -unsaturated amide 113d	39
2.10	Data of α,β -unsaturated amide 114a	41
2.11	Data of α,β -unsaturated amide 114b	43
2.12	Data of α,β -unsaturated amide 114c	45
2.13	Data of α,β -unsaturated amide 114d	47
2.14	Data of dimethyl itaconate–anthracene adduct (($\pm$)- 74)	49
2.15	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 115b-i	52
2.16	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 115b-ii	54
2.17	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 115c-i	57
2.18	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 115c-ii	60
2.19	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 115d-i	62
2.20	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 115d-ii	64
2.21	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116a-i	68
2.22	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116a-ii	70
2.23	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116b-i	72
2.24	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116b-ii	74
2.25	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116c-i	77
2.26	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116c-ii	79

LIST OF TABLES (CONTINUED)

Table		Page
2.27	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116d-i	82
2.28	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 116d-ii	84
2.29	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117a-i	88
2.30	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117a-ii	89
2.31	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117b-i	92
2.32	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117b-ii	94
2.33	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117c-i	96
2.34	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117c-ii	98
2.35	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117d-i	101
2.36	Data of spirocyclopentanone–anthracene adduct ($\pm$)- 117d-ii	103
3.1	^1H -NMR data of piperine (75)	106
3.2	^1H -NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 76-i and ($\pm$)- 76-ii	109
3.3	^1H -NMR data of cyclopentanones ($\pm$)- 134-i and ($\pm$)- 134-ii	116
3.4	^1H -NMR data of pentadiene amide 112b	120
3.5	^1H -NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 115b-i and ($\pm$)- 115b-ii	123
3.6	^1H -NMR data of pentadiene amide 112c	126
3.7	^1H -NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 115c-i and ($\pm$)- 115c-ii	128
3.8	^1H -NMR data of pentadiene amide 112d	132
3.9	^1H -NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 115d-i and ($\pm$)- 115d-ii	134
3.10	^1H -NMR data of α,β -unsaturated amide 113a	139
3.11	^1H -NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 116a-i and ($\pm$)- 116a-ii	141
3.12	^1H -NMR data of α,β -unsaturated amide 113b	145
3.13	^1H -NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 116b-i and ($\pm$)- 116b-ii	147

LIST OF TABLES (CONTINUED)

Table		Page
3.14	¹ H-NMR data of α,β -unsaturated amide 113c	151
3.15	¹ H-NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 116c-i and ($\pm$)- 116c-ii	153
3.16	¹ H-NMR data of α,β -unsaturated amide 113d	157
3.17	¹ H-NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 116d-i and ($\pm$)- 116d-ii	159
3.18	¹ H-NMR data of α,β -unsaturated amide 114a	163
3.19	¹ H-NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 117a-i and ($\pm$)- 117a-ii	165
3.20	¹ H-NMR data of α,β -unsaturated amide 114b	168
3.21	¹ H-NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 117b-i and ($\pm$)- 117b-ii	170
3.22	¹ H-NMR data of α,β -unsaturated amide 114c	173
3.23	¹ H-NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 117c-i and ($\pm$)- 117c-ii	175
3.24	¹ H-NMR data of α,β -unsaturated amide 114d	179
3.25	¹ H-NMR data of spirocyclopentanone–anthracene adducts ($\pm$)- 117d-i and ($\pm$)- 117d-ii	181
3.26	Bioactivity and cytotoxicity tests of spirocyclopentanone– anthracene adducts (($\pm$)- 76-i and ($\pm$)- 76-ii) and cyclopentanones (($\pm$)- 134-i and ($\pm$)- 134-ii)	185
3.27	Bioactivity and cytotoxicity tests of spirocyclopentanone– anthracene adducts (($\pm$)- 115b-i , <i>ii</i> – ($\pm$)- 115d-i , <i>ii</i>)	186
3.28	Bioactivity and cytotoxicity tests of spirocyclopentanone– anthracene adducts (($\pm$)- 116a-i , <i>ii</i> – ($\pm$)- 116d-i , <i>ii</i>)	187
3.29	Bioactivity and cytotoxicity tests of spirocyclopentanone– anthracene adducts (($\pm$)- 117a-i , <i>ii</i> – ($\pm$)- 117d-i , <i>ii</i>)	188

LIST OF FIGURES

Figure		Page
1.1	The life cycles of malaria disease	3
1.2	Mechanisms of action of 4-aminoquinolines	6
1.3	4-Aminoquinoline derivatives	7
1.4	Arylamino alcohols derivatives	8
1.5	8-Aminoquinoline derivatives	8
1.6	Iron (II)-mediated formation of primary or secondary carbon radicals from artemisinin	9
1.7	The “iron-triggered cluster bomb”: the mechanism of action of artemisinins, carbon-based radicals, deactivating proteins more or less indiscriminately	10
1.8	Recent results suggest that; these radicals specifically inhibit a sarcoplasmic/endoplasmic reticulum Ca^{2+} ATPase called <i>PfATP6</i>	10
1.9	Artemisinin and synthetic peroxide derivatives	11
1.10	Chimeric molecules	12
1.11	Antifolates	12
1.12	Hydroxynaphthoquinone derivatives	13
1.13	Antibiotics	14
1.14	Diamidines	15
1.15	Inhibitors of phospholipid metabolism	15
1.16	Inhibitors of isoprenoid biosynthesis	16
1.17	Dihydroethanoanthracenic (DEA) derivatives	18
1.18	Alkaloid compounds from piper	18
1.19	Structure of dipiperamides	19
1.20	Structure of chabamide	19
1.21	Structure of cinnamic acid derivatives	20
3.1	^1H -NMR spectrum of piperine (75)	107

LIST OF FIGURES (CONTINUED)

Figure		Page
3.2	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 76-i	110
3.3	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 76-ii	110
3.4	NOE correlations observed and X-ray crystallographic picture (PLATON technique) of spirocyclopentanone–anthracene adduct (±)- 76-i	111
3.5	NOE correlations observed and X-ray crystallographic picture (ORTEP technique) of spirocyclopentanone–anthracene adduct (±)- 76-ii	111
3.6	¹ H-NMR spectrum of cyclopentanone (±)- 134-i	117
3.7	¹ H-NMR spectrum of cyclopentanone (±)- 134-ii	117
3.8	NOE correlations observed of cyclopentanone (±)- 134-i and (±)- 134-ii	118
3.9	¹ H-NMR spectrum of pentadiene amide 112b	121
3.10	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 115b-i	124
3.11	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 115b-ii	124
3.12	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 115b-i and (±)- 115b-ii	125
3.13	¹ H-NMR spectrum of pentadiene amide 112c	127
3.14	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 115c-i	130
3.15	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 115c-ii	130
3.16	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 115c-i and (±)- 115c-ii	131
3.17	¹ H-NMR spectrum of pentadiene amide 112d	133

LIST OF FIGURES (CONTINUED)

Figure		Page
3.18	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 115d-i	136
3.19	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 115d-ii	136
3.20	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 115d-i and (±)- 115d-ii	137
3.21	¹ H-NMR spectrum of α,β -unsaturated amide 113a	140
3.22	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116a-i	142
3.23	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116a-ii	143
3.24	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 116a-i and (±)- 116a-ii	143
3.25	¹ H-NMR spectrum of α,β -unsaturated amide 113b	146
3.26	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116b-i	149
3.27	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116b-ii	149
3.28	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 116b-i and (±)- 116b-ii	150
3.29	¹ H-NMR spectrum of α,β -unsaturated amide 113c	152
3.30	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116c-i	155
3.31	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116c-ii	155
3.32	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 116c-i and (±)- 116c-ii	156
3.33	¹ H-NMR spectrum of α,β -unsaturated amide 113d	158

LIST OF FIGURES (CONTINUED)

Figure		Page
3.34	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116d-i	161
3.35	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 116d-ii	161
3.36	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 116d-i and (±)- 116d-ii	162
3.37	¹ H-NMR spectrum of α,β -unsaturated amide 114a	164
3.38	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117a-i	166
3.39	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117a-ii	166
3.40	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 117a-i and (±)- 117a-ii	167
3.41	¹ H-NMR spectrum of α,β -unsaturated amide 114b	169
3.42	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117b-i	171
3.43	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117b-ii	171
3.44	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 117b-i and (±)- 117b-ii	172
3.45	¹ H-NMR spectrum of α,β -unsaturated amide 114c	174
3.46	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117c-i	177
3.47	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117c-ii	177
3.48	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 117c-i and (±)- 117c-ii	178
3.49	¹ H-NMR spectrum of α,β -unsaturated amide 114d	180

LIST OF FIGURES (CONTINUED)

Figure		Page
3.50	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117d-i	182
3.51	¹ H-NMR spectrum of spirocyclopentanone–anthracene adduct (±)- 117d-ii	182
3.52	NOE correlations observed of spirocyclopentanone–anthracene adducts (±)- 117d-i and (±)- 117d-ii	183
3.53	The lock and key model	189
3.54	Competitive inhibitors bind reversibly to the enzyme	191

LIST OF SCHEMES

Scheme		Page
1.1	Syntheses of spirocyclopentanone–anthracene adducts ((±)- 76-i and (±)- 76-ii)	16
1.2	Synthesis of dimethyl itaconate anthracene adduct ((±)- 74)	17
1.3	Applications of dimethyl itaconate anthracene adduct ((±)- 74)	17
1.4	Preparation of amide derivatives (112b-d – 114a-d)	20
1.5	Summarization of the syntheses of spirocyclopentanone–anthracene adduct derivatives ((±)- 115b-d – (±)- 117a-d)	21
3.1	Tandem Michael addition-Dieckmann condensation reactions of (±)- 76-i and (±)- 76-ii	108
3.2	Mechanism of tandem Michael addition-Dieckmann condensation reactions of (±)- 76-i and (±)- 76-ii	112
3.3	Transition state of adducts (±)- 76-iii – (±)- 76-v from tandem Michael addition-Dieckmann condensation reactions	113
3.4	Transition state of adducts (±)- 76-vi – (±)- 76-viii from tandem Michael addition-Dieckmann condensation reactions	114
3.5	Tandem Michael addition-Dieckmann condensation reactions (±)- 134-i and (±)- 134-ii	115
3.6	Mechanism of tandem Michael addition-Dieckmann condensation reactions of (±)- 134-i and (±)- 134-ii	119
3.7	Preparation reaction of pentadiene amide 112b	120
3.8	The mechanism of nucleophilic acyl substitution reaction	121
3.9	Tandem Michael addition-Dieckmann condensation reactions of (±)- 115b-i and (±)- 115b-ii	122
3.10	Preparation reaction of pentadiene amide 112c	126
3.11	Tandem Michael addition-Dieckmann condensation reactions of (±)- 115c-i and (±)- 115c-ii	127
3.12	Preparation reaction of pentadiene amide 112d	132

LIST OF SCHEMES (CONTINUED)

Scheme		Page
3.13	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 115d-i and ($\pm$)- 115d-ii	133
3.14	Preparation reaction of α,β -unsaturated amide 113a	139
3.15	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 116a-i and ($\pm$)- 116a-ii	140
3.16	Preparation reaction of α,β -unsaturated amide 113b	145
3.17	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 116b-i and ($\pm$)- 116b-ii	146
3.18	Preparation reaction of α,β -unsaturated amide 113c	151
3.19	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 116c-i and ($\pm$)- 116c-ii	152
3.20	Preparation reaction of α,β -unsaturated amide 113d	157
3.21	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 116d-i and ($\pm$)- 116d-ii	158
3.22	Preparation reaction of α,β -unsaturated amide 114a	163
3.23	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 117a-i and ($\pm$)- 117a-ii	164
3.24	Preparation reaction of α,β -unsaturated amide 114b	168
3.25	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 117b-i and ($\pm$)- 117b-ii	169
3.26	Preparation reaction of α,β -unsaturated amide 114c	173
3.27	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 117c-i and ($\pm$)- 117c-ii	174
3.28	Preparation reaction of α,β -unsaturated amide 114d	179
3.29	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 117d-i and ($\pm$)- 117d-ii	180
3.30	Preparation of methyl itaconate-anthracene adduct dimers ($\pm$)- 146a-c	184

LIST OF SCHEMES (CONTINUED)

Scheme		Page
3.31	Tandem Michael addition-Dieckmann condensation reactions of ($\pm$)- 147a-c	184
3.32	Reaction of the reversible inhibitors	193
3.33	Reaction of the irreversible inhibitors	193
4.1	Tandem Michael addition-Dieckmann condensation reactions of racemic spirocyclopentanone–anthracene adducts ($\pm$)- 76-i , - <i>ii</i> and (($\pm$)- 115b-i , - <i>ii</i> – ($\pm$)- 115d-i , - <i>ii</i>	195
4.2	Tandem Michael addition-Dieckmann condensation reactions of racemic spirocyclopentanone–anthracene adducts ($\pm$)- 116a-i , - <i>ii</i> – ($\pm$)- 116d-i , - <i>ii</i>	196
4.3	Tandem Michael addition-Dieckmann condensation reactions of racemic spirocyclopentanone–anthracene adducts ($\pm$)- 117a-i , - <i>ii</i> – ($\pm$)- 117d-i , - <i>ii</i>	196
4.4	Tandem Michael addition-Dieckmann condensation reactions of racemic cyclopentanones ($\pm$)- 134-i and ($\pm$)- 134-ii	196

ABBREVIATIONS AND SYMBOLS

Ar	Aryl
b.p.	Boiling point
brs	broad singlet
<i>n</i> -BuLi	<i>normal</i> -Butyllithium
c	Concentration
calc.	Calculated
d	Doublet
dd	Double doublet
ddd	Doublet of double doublet
dq	Double of quartet
equiv.	Equivalent
EtOAc	Ethyl acetate
Et ₃ N	Triethylamine
<i>i</i> -C ₃ H ₇	<i>iso</i> -Propyl
IC ₅₀	50% Inhibitory concentration
<i>J</i>	Coupling constant
h	Hour
Hz	Hertz
FT-IR	Fourier transform infrared radiation
lit.	Literature
LDA	Lithium diisopropylamide
m	Multiplet
min	Minute
ml	Milliliter
m.p.	Melting point
Me	Methyl
MHz	Megahertz
NMR	Nuclear magnetic resonance

ABBREVIATIONS AND SYMBOLS (CONTINUED)

MOESY(NOE)	Nuclear overhauser enhancement spectroscopy
MW	Molecular weight
m/z	mass-to-charge ratio
$n\text{-C}_4\text{H}_9$	<i>normal</i> -Butyl
PLC	Preparative layer chromatography
ppm	Parts per million (in NMR)
q	Quartet
RT = rt	Room temperature (°C)
R_f	Retardation factor
s	Singlet
t	Triplet
T	Temperature (°C)
THF	Tetrahydrofuran
TLC	Thin layer chromatography
ν	Wavenumber (cm^{-1})
δ	Chemical shift (ppm)
λ	Wavelength (cm^{-1})
μg	Microgram